跳至主要内容
临床试验/NCT06684561
NCT06684561尚未招募不适用

EARLY FEASIBILITY STUDY: SAFETY AND EFFICACY OF PHOTON INFUSION SET

Sheba Medical Center0 个研究点目标入组 40 人开始时间: 2024年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
40
主要终点
Primary Effectiveness Endpoint

研究概览

简要总结

Study 1:

The purpose of this study is to evaluate safety and efficacy of Photon infusion sets (PIS) with new PFAS-free cannula (catheter) in adult patients with Type 1 diabetes for up to 10 days and 6 hours.

This is a 1-center, prospective, open-label, 1-arm study with type 1 patients with diabetes on 780G insulin pump therapy with Guardian™ 4 Continuous Glucose Monitoring (CGM). All subjects will be instructed to change infusion sets every 246 hours (10 days & 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.

After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of <6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.

Photon infusion sets with 6-mm and 9-mm cannula length will be supplied for this study, with selection based on subjects' needs and doctor's recommendation. Subjects will change insulin reservoirs at least every 7 days (the labelled wear duration of the Extended reservoir). The infusion set(s) or reservoir(s) can be replaced independent of each other. The date and time of each infusion set insertion will be recorded in a Daily Log (Diary) which will include the causes of early removal, if occurs.

Study 2: If Study 1 is successful, the same study designed as illustrated in Figure 1 may be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of type 1 diabetes for at least one year
  • Using a MiniMed™ 780G Insulin pump with Guardian sensor
  • Age 18 to 80 years
  • Hemoglobin A1c level less than or equal to 10%
  • Not currently known to be pregnant, nor planning pregnancy during the study.
  • Willingness to follow the protocol and sign the informed consent

排除标准

  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.
  • Pregnant or lactating females
  • Subject has Glycosylated hemoglobin (HbA1c)< 10 % at time of screening.

结局指标

主要结局

Primary Effectiveness Endpoint

时间窗: 12 months

The primary outcome is to have no more than 16% of infusion set failures due to "unexplained hyperglycemia" Definition of unexplained hyperglycemia: o The study meter glucose \>250 mg/dL (\>3 hours post-meal) which may include time during subject's sleeping hours. * Failure of a correction dose(s) to lower the study meter glucose by at least 50 mg/dL within 1 hour. * One additional correction dose may be given after first correction dose and recommended to use the bolus calculator

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Prof. Amir Tirosh

Prof. Amir Tirosh

Sheba Medical Center

相似试验